Board summary
Key figures
50,410
Registered population
60.6% aged 18–64
16.3%
Aged 65+
ICB 20.0% · England 17.9%
18.7%
Ethnic minority (non-White)
16.1% Asian · England 9.6%
66.6%
In IMD quintile 1
ICB 30.6% · England 21.0%
~28,298
Core20 residents (est.)
Resident basis; registered basis ~35,124 · see page 3
7,800
Hypertension register
+2.38% in 3 yrs · England +5.60%
678
SMI register
64% of Hyndburn's
1,166
COPD register
Reviews +9.94% in 3 yrs
Forecast to 2030
8,404
Hypertension patients, 2030
+604 on today
74.8%
QRISK ≥20% on statins, 2030
+4.83pp over 3 yrs
3.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Non-frail diabetes and under-80 blood pressure trail.
Non-frail diabetes HbA1c control is 48.5% (England 57.4%) and under-80 hypertension control is 64.9% (England 67.8%), which could reflect unverified working-age access barriers.
Asthma reviews and cervical screening lag England.
Asthma review completion is 59.8% (England 65.7%, leaving about 1,300 register patients unreviewed), while cervical screening aged 25-49 reaches 58.2% (England 66.8%).
Older hypertension and frail diabetes beat England.
Blood pressure control aged 80+ reaches 84.3% (England 81.2%) and frail diabetes HbA1c control reaches 83.9% (England 81.9%), demonstrating strong registered-patient delivery.
Population, age and ethnicity
A younger population with 23.1% aged 0-17 shapes clinical demand across practices
Across 50,410 registered patients, 23.1% (11,649) are aged 0-17, exceeding Hyndburn (22.2%), the ICB (19.6%), and England (19.6%). Patients aged 65+ comprise 16.3% (8,211), below Hyndburn (16.5%), England (17.9%), and the ICB (20.0%). Census estimates show an Asian or Asian British resident population of 16.1%, above Hyndburn (15.1%), the ICB (9.4%), and England (9.6%), with 39.8% at Arg Healthcare and 30.9% at Richmond Medical Centre. Age figures reflect registered patients, while ethnic estimates derive from area residents.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Hyndburn local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Hyndburn LA) | 1,997 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.9% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 48.5% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Hyndburn LA) | 1,099 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Hyndburn LA) | 14.2 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 66.6% across the PCN but divides concentration from absolute volume
The PCN Core20 cohort is 66.6%, above Hyndburn (54.1%), the ICB (30.6%) and England (21.0%), with an average IMD decile of 2.8. Practice concentration spans 40.3 pp: Arg Healthcare has a 95.8% share (4,605 estimated patients) and Richmond Medical Centre has 93.1% (6,164 estimated patients). By volume, Peel House Medical Practice has 11,016 estimated patients (59.4%) and Oswald Medical Centre has 11,009 (67.8%). Practice estimates sum to 35,124 registered patients, whereas area resident counts total 28,298; reconciling these different denominators is required before committing outreach resources.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
678
SMI register
1.38% recorded prevalence
447
Learning disability register
0.91% recorded prevalence
30
Care homes, 879 beds
In the PCN catchment
10.2%
Provide unpaid care
Hyndburn, Census 2021
Recorded prevalence is 0.9% for learning disability (447 patients) and 1.4% for severe mental illness (678 patients), alongside 30 catchment care homes with 879 beds. Hyndburn borough data show a 10.2% unpaid carer rate and 2 people sleeping rough in autumn 2025, which cannot be directly extrapolated to PCN practice lists.
Severe mental illness: physical health checks
For severe mental illness, annual blood pressure checks reach 77.7% (England 83.4%), with Richmond Medical Centre at 67.7%, and BMI recording reaches 72.5% (England 82.1%) across 678 registered patients.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,800
Hypertension register
+2.38%
Register growth, 3 yrs
Hyndburn +2.89% · England +5.60%
+0.59pp
BP control, under 80
≤140/90 · +1.28pp aged 80+
+604
More patients by 2030
Forecast 8,404 (16.68%)
Hypertension case-finding and control
Recorded hypertension prevalence is 15.9% (7,800 patients), above England (15.2%) but below Hyndburn (16.4%) and the ICB (17.2%). Among patients aged 80 and over, blood pressure control reaches 84.3%, exceeding England (81.2%) and the ICB (81.8%). Conversely, control under 80 is 64.9%, trailing England (67.8%), Hyndburn (66.4%) and the ICB (67.1%). Overall treatment to target is 68.8% (England 70.3%). This divergence could reflect working-age access barriers, which an audit would test. Under-80 blood pressure control lags comparators while older cohorts exceed them, indicating that targeted recall and flexible review access for working-age patients should be prioritised.
Lipids and statins
For primary CVD prevention in diabetes aged 40 and over, statin coverage is 70.6%, trailing England (73.2%) and the ICB (71.3%). Conversely, secondary prevention in diabetes with CVD reaches 86.8% (England 84.4%), while QRISK 20% or higher treatment is 63.9% (England 63.6%). Primary prevention in diabetes lags national rates, indicating scope to review statin prescribing.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 106,611 | £1.40 | £1.64 | £1.86 | £149,255 |
| Cardiovascular (all), 2025 | 141,025 | £2.97 | £3.38 | £3.33 | £418,844 |
In 2026, the PCN prescribed 106,611 lipid-regulating items at £1.40 per item, below England (£1.86) and the ICB (£1.64), spending £49,041 less than England's unit cost and £25,587 less than the ICB's. Lower unit cost indicates spending is below national and ICB averages across captured items.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+20.19%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−6.49%
Asthma prevalence, PCN 3-yr % change
Over 2023 to 2025, asthma reviews rose +20.2% (England +4.4%), yet current review completion is 59.8% (England 65.7%), leaving about 1,300 register patients unreviewed. Second-hand smoke recording for patients aged 6-19 is 66.9% (England 78.8%), while asthma prescribing in ages 5-19 is 1,620 per 1,000 (England 1,488). Meanwhile, COPD reviews reached 71.7% (England 76.4%) and the COPD register fell 2.3% over 2023 to 2025 (England +2.6%).
Cancer register and children's immunisation
Childhood immunisations in Q1 2025/26 trail the 95.0% target: 6-in-1 at 12 months is 83.1% (England 91.0%), age-5 4-in-1 booster is 76.7% (England 80.9%, 18.3 pp below target), and age-5 MMR shows an 8 pp contrast between dose 1 (90.0%) and dose 2 (82.0%, England 82.8%). Cancer prevalence is 3.4% (England 3.8%), with 1,676 patients. Lower pre-school uptake could leave cohorts vulnerable to preventable infection.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022, 52.4% of staged cancers (4,642 of 8,863) across NHS Lancashire and South Cumbria ICB were diagnosed at stage 1 or 2, trailing England (55.3%) and 22.6 pp below the 75.0% national ambition by 2028, with known stage recorded for 74.6% (8,863 of 11,883). Reaching 75.0% across the ICB would require about 2,010 extra early-stage diagnoses annually; staging is not captured at PCN level. PCN cervical screening coverage aged 25-49 is 58.2% (England 66.8%), dropping to 48.2% at Richmond Medical Centre and 54.2% at Oswald Medical Centre. Breast screening aged 53-70 is 66.6% (England 69.9%). Lower PCN screening coverage may constrain opportunities to detect early-stage cancer.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), East Lancashire Hospitals NHS Trust achieved 73.2% against the 85.0% 62-day cancer referral to treatment standard, ahead of England (71.2%) but behind the ICB (73.6%), Lancashire Teaching Hospitals NHS Foundation Trust (75.0%) and Northern Care Alliance NHS Foundation Trust (78.6%). The trust met the 75.0% 28-day faster diagnosis standard at 81.5% and the 96.0% 31-day combined treatment standard at 98.1%. Diagnostic waits over 6 weeks at the trust were 0.4% for MRI and 0.1% for CT. These figures are consistent with prompt secondary care diagnostic turnaround alongside wider 62-day pathway delays.
| Pathways within standard (%) | East Lancashire | Northern Care Alliance | Lancashire | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.50 | 75.20 | 82.90 | 78.39 | 79.32 |
| 31-day treatment (96%) | 98.11 | 94.54 | 89.43 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 73.16 | 78.65 | 75.04 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Lancashire | Northern Care Alliance | Lancashire | England |
|---|---|---|---|---|
| MRI | 0.43 | 5.09 | 2.41 | 21.40 |
| CT | 0.15 | 4.10 | 14.97 | 9.92 |
| Echocardiography | 0.00 | 31.48 | 13.85 | 28.48 |
| Colonoscopy | 0.95 | 40.04 | 0.00 | 30.83 |
| Gastroscopy | 1.16 | 36.48 | 0.00 | 29.02 |
| All 15 DM01 tests | 3.25 | 15.71 | 26.65 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In Jun 2026 (provisional), 56.9% of community service contacts for Hyndburn borough residents (72,000 of 126,445) involved adults aged 65+, describing borough-wide system activity rather than PCN performance. These borough-level contacts reflect wider system engagement with older residents rather than PCN-specific delivery.
Practice variation and patient experience
Phone access spans 39.0 pp across practices despite high clinical QOF achievement
In 2025/26, practice clinical QOF achievement ranged from 92.0% at Arg Healthcare to 100.0% at Richmond Medical Centre (England 97.1%). Conversely, vaccination and immunisation achievement trailed England (55.2%), spanning 15.6% at Accrington Victoria GP Practice and Richmond Medical Centre to 28.5% at Arg Healthcare (a 12.9 pp spread).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Peel House | 90 | 59.4 | 50.1% | 62.8% | 78.3% |
| Oswald | 93 | 67.8 | 59.1% | 76.4% | 74.6% |
| Arg Healthcare | 84 | 95.8 | 65.3% | 73.6% | 71.0% |
| Accrington | 128 | 55.5 | 32.8% | 73.9% | 61.0% |
| Richmond | 93 | 93.1 | 26.3% | 76.8% | 50.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Dementia fell 7.9% (England +6.0%) while asthma reviews rose 20.2% (England +4.4%)
Over 2023 to 2025, relative 3-year register changes trailed England for dementia, down 7.9% (England +6.0%), stroke, down 6.3% (England +2.3%), and asthma, down 6.5% (England +0.5%). Conversely, review processes improved: asthma reviews grew 20.2% (England +4.4%) and non-frail diabetes HbA1c control rose 13.8% (England +4.4%). Rapid growth has not erased current gaps: non-frail diabetes control is 48.5% (England 57.4%) and asthma review completion is 59.8% (England 65.7%). Clinical audit could assess whether register contractions reflect under-diagnosis or list validation.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Stroke register
Asthma register
Breast screening (53-70)
COPD register
Asthma reviews
Diabetes HbA1c control
COPD reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Hyndburn | Asset | PCN | Hyndburn |
|---|---|---|---|---|---|
| Care homes (catchment) | 30 (879 beds) | n/a | Schools (catchment) | 56 | n/a |
| Children's centres | 6 | 7 | Places of worship | 45 | 55 |
| Libraries | 3 | 5 | Primary schools (LA maintained) | 24 | 26 |
| Primary academies | 6 | 7 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma annual review recall
Asthma annual review completion is 59.8% (England 65.7%, ICB 65.0%), leaving 1,316 (about 1,300) of 3,274 register patients unreviewed; age 6-19 second-hand smoke recording is 66.9% (England 78.8%). For discussion: run a single-template asthma recall offering after-school and extended-hours slots, pairing concentration outreach with high-volume clinics. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
SMI physical health check outreach
Across 678 SMI register patients, annual blood pressure checks reach 77.7% (England 83.4%, ICB 79.8%; 67.7% at Richmond Medical Centre) and BMI recording is 72.5% (England 82.1%, ICB 76.8%). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Working-age hypertension and diabetes review
With 7,800 on the hypertension register, under-80 BP control is 64.9% (England 67.8%, ICB 67.1%); non-frail diabetes HbA1c <=58 mmol/mol in 2024/25 is 48.5% (1,405 of 2,898; England 57.4%). For discussion: test pharmacist-led recall, remote blood pressure monitoring and extended-hours diabetes and hypertension clinics for working-age patients. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Tailored ethnic minority health engagement (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Working-age hypertension recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool booster recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Primary care telephony access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · SMI physical health check outreach (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN & Practice |
| Option 3 · Working-age hypertension and diabetes review (p12) | Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
